Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

BioScrip to Present at BMO Capital Markets' Focus on Healthcare Conference


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-07-23 04:11:06 -

- BioScrip, Inc. (Nasdaq: BIOS) today announced that it will present at the BMO Capital Markets Focus on Healthcare 2008 Investor Conference, to be held August 5-6, 2008, at the Millennium Broadway Hotel in New York City.

BioScrip's Chairman and CEO, Richard H. Friedman, and Stanley G. Rosenbaum, Executive Vice President and CFO will present Tuesday, August 5th at

9:00 a.m. ET (Eastern Time). Investors may access the live audio webcast of BioScrip's presentation at the following link: www.bmocm.com/conferences/2008healthcare/webcast/default.aspx. The webcast replay of the presentation may also be accessed via the company's website at www.bioscrip.com under the Investors section.

About BioScrip, Inc.

BioScrip, Inc. (www.bioscrip.com) (Nasdaq: BIOS) is a specialty pharmaceutical healthcare organization that partners with patients, physicians, healthcare payors and pharmaceutical manufacturers to provide access to medications and management solutions to optimize outcomes for chronic and other complex healthcare conditions.

BioScrip, Inc.
Craig Allison
Director, Corporate Communications
Tel: 914-460-1636
callison@BioScrip.com
or
In-Site Communications
Lisa M. Wilson
Tel: 917-543-9932
lwilson@insitecony.com


Disclaimer: (c) 2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.


Terms & Conditions | About us | Contact PR-inside.com